272 related articles for article (PubMed ID: 15685615)
1. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins.
Buchwald B; Ahangari R; Weishaupt A; Toyka KV
Muscle Nerve; 2005 Apr; 31(4):487-94. PubMed ID: 15685615
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
Buchwald B; Ahangari R; Weishaupt A; Toyka KV
Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
[TBL] [Abstract][Full Text] [Related]
3. Lambert-Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis.
Takamori M
J Neuroimmunol; 2008 Sep; 201-202():145-52. PubMed ID: 18653248
[TBL] [Abstract][Full Text] [Related]
4. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse.
Waterman SA; Lang B; Newsom-Davis J
Ann Neurol; 1997 Aug; 42(2):147-56. PubMed ID: 9266723
[TBL] [Abstract][Full Text] [Related]
5. Lambert-Eaton myasthenic syndrome IgG depletes presynaptic membrane active zone particles by antigenic modulation.
Nagel A; Engel AG; Lang B; Newsom-Davis J; Fukuoka T
Ann Neurol; 1988 Oct; 24(4):552-8. PubMed ID: 2853605
[TBL] [Abstract][Full Text] [Related]
6. Action of Lambert-Eaton myasthenic syndrome IgG at mouse motor nerve terminals.
Prior C; Lang B; Wray D; Newsom-Davis J
Ann Neurol; 1985 Jun; 17(6):587-92. PubMed ID: 2992356
[TBL] [Abstract][Full Text] [Related]
7. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment.
Quartel A; Turbeville S; Lounsbury D
Curr Med Res Opin; 2010 Jun; 26(6):1363-75. PubMed ID: 20377318
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of intravenous immunoglobulin for treatment of Lambert-Eaton myasthenic syndrome without anti-presynaptic P/Q-type voltage-gated calcium channel antibodies: a case report.
Okada A; Koike H; Nakamura T; Motomura M; Sobue G
Neuromuscul Disord; 2015 Jan; 25(1):70-2. PubMed ID: 25444432
[TBL] [Abstract][Full Text] [Related]
9. Specificity of Lambert-Eaton myasthenic syndrome immunoglobulin for nerve terminal calcium channels.
Hewett SJ; Atchison WD
Brain Res; 1992 Dec; 599(2):324-32. PubMed ID: 1363289
[TBL] [Abstract][Full Text] [Related]
10. Cross-linking of presynaptic calcium channels: a mechanism of action for Lambert-Eaton myasthenic syndrome antibodies at the mouse neuromuscular junction.
Peers C; Johnston I; Lang B; Wray D
Neurosci Lett; 1993 Apr; 153(1):45-8. PubMed ID: 8390031
[TBL] [Abstract][Full Text] [Related]
11. Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmission.
Cavill D; Waterman SA; Gordon TP
Arthritis Rheum; 2003 Dec; 48(12):3597-602. PubMed ID: 14674012
[TBL] [Abstract][Full Text] [Related]
12. Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate.
Fukuoka T; Engel AG; Lang B; Newsom-Davis J; Vincent A
Ann Neurol; 1987 Aug; 22(2):200-11. PubMed ID: 3310854
[TBL] [Abstract][Full Text] [Related]
13. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Newsom-Davis J
Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
[TBL] [Abstract][Full Text] [Related]
14. Myasthenia gravis and myasthenic syndrome.
Antozzi C
Neurol Sci; 2003 Oct; 24 Suppl 4():S260-3. PubMed ID: 14598056
[TBL] [Abstract][Full Text] [Related]
15. Stimulated single-fiber electromyography in Lambert-Eaton myasthenic syndrome.
Chaudhry V; Watson DF; Bird SJ; Cornblath DR
Muscle Nerve; 1991 Dec; 14(12):1227-30. PubMed ID: 1662773
[TBL] [Abstract][Full Text] [Related]
16. [Neurogenic electromyographic activity in a patient with non-paraneoplasic Lambert-Eaton syndrome].
Lapergue B; Lefaucheur JP; Bourahoui A; Nordine T; Hosseini H; Créange A
Rev Neurol (Paris); 2007 Dec; 163(12):1227-31. PubMed ID: 18355470
[TBL] [Abstract][Full Text] [Related]
17. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
18. 3,4-diaminopyridine for the treatment of Lambert-Eaton myasthenic syndrome.
Wirtz PW; Titulaer MJ; Gerven JM; Verschuuren JJ
Expert Rev Clin Immunol; 2010 Nov; 6(6):867-74. PubMed ID: 20979551
[TBL] [Abstract][Full Text] [Related]
19. Lambert-Eaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity.
Lang B; Vincent A; Murray NM; Newsom-Davis J
Ann Neurol; 1989 Mar; 25(3):265-71. PubMed ID: 2543262
[TBL] [Abstract][Full Text] [Related]
20. Neuromuscular blockade by IgG antibodies from patients with Guillain-Barré syndrome: a macro-patch-clamp study.
Buchwald B; Toyka KV; Zielasek J; Weishaupt A; Schweiger S; Dudel J
Ann Neurol; 1998 Dec; 44(6):913-22. PubMed ID: 9851436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
